Enikia is an innovative dietary supplement that emerged after years of research and development starting in 2015 and ending in 2021.
Enikia's formula combines cutting-edge science with natural ingredients to offer a comprehensive solution in the field of modern medicine.
Dr. Horacio Astudillo witnessed how this supplement transformed the quality of life of those who used it, validating its effectiveness and relevance in health care. Enikia represents not only a product, but a promise of hope and vitality for a healthier and fuller life.
TIMELINE
2015
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 222470
Development and validation of a new supplement and antiglycant for metabolic syndrome. Part I
2015
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 222470
Development and validation of a new supplement and antiglycant for metabolic syndrome. Part I
2016
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 231815
Development and validation of a new nutraceutical for the treatment of metabolic syndrome. Part II
2016
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 231815
Development and validation of a new nutraceutical for the treatment of metabolic syndrome. Part II
2017
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 242306
Development and validation of a new nutraceutical for the treatment of metabolic syndrome. Part III
2017
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 242306
Development and validation of a new nutraceutical for the treatment of metabolic syndrome. Part III
2018 – 2021
INTELLECTUAL PROPERTY
During these years, the focus was on rigorous research and innovative development, granting us patents in 24 countries.
United States – Mexico – OAPI – Russia – Panama – China – Hong Kong - India
2018 – 2021
INTELLECTUAL PROPERTY
During these years, the focus was on rigorous research and innovative development, granting us patents in 24 countries.
United States – Mexico – OAPI – Russia – Panama – China – Hong Kong - India
2022 – 2023
ENIKIA® GOES ON THE MARKET
It is officially launched as a dietary supplement that combines amino acids and antioxidants, with nanotechnology to prevent and reverse cellular damage caused by chronic-degenerative diseases.
2022 – 2023
ENIKIA® GOES ON THE MARKET
It is officially launched as a dietary supplement that combines amino acids and antioxidants, with nanotechnology to prevent and reverse cellular damage caused by chronic-degenerative diseases.
Patents –
United States -Combination of bioenergetic and nutra-epigenetic metabolic regulators, nutraceutical compounds in conventional and nanotechnological combinations to reverse and prevent cellular senescence accelerated by chronic damage produced by diabetes and other complex chronic-degenerative diseases. (US Patent 10 285 963 B2)
Mexico -Combination of bioenergetic and nutra-epigenetic metabolic regulators, nutraceutical compounds in conventional and nanotechnological combinations to reverse and prevent cellular senescence accelerated by chronic damage produced by diabetes and other complex chronic-degenerative diseases.(Patent MX/a/2017/007448)
OAPI (17 countries) -Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes. (Patent WO2017213486A2)
Russia -Use of a composition consisting of the amino acids glycine, arginine, cysteine and resveratrol to reduce the severity of diabetes and high body fat, cholesterol, uric acid, blood glucose and accelerated aging in animals and humans. (Patent RU2749950C2)
Panama – Combination of bioenergetic and nutra-epigenetic metabolic regulators, nutraceutical compounds in conventional and nanotechnological combinations to reverse and prevent cellular senescence accelerated by chronic damage produced by diabetes and other complex chronic-degenerative diseases. (Patent 92465-01)
China – Combination of metabolic regulators and compounds to prevent and reduce the severity of chronic damage caused by diabetes. (Patent CN 109890369 B)
Hong Kong – Combination of metabolic regulators and compounds to prevent and reduce the severity of chronic damage caused by diabetes. (Patent HK40010029)
- India – Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes. (Patent 461531)
